BIOCRYST PHARMACEUTICALS, INC. Finance Lease, Liability, Current
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Finance Lease, Liability, Current of $1.09 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:FinanceLeaseLiabilityCurrent · last filed 2026-08-05
- 2026-06-30: Finance Lease, Liability, Current $1.09M.
- 2026-03-31: Finance Lease, Liability, Current $1.24M.
- 2025-12-31: Finance Lease, Liability, Current $1.31M.
- 2025-09-30: Finance Lease, Liability, Current $1.44M.
| Period end | Finance Lease, Liability, Current |
|---|---|
| 2026-06-30 | $1.09M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.24M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $1.31M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $1.44M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $1.62M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $1.79M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $1.83M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.84M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $1.68M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $1.64M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $1.59M 10-K · filed 2025-02-25 |
| 2022-12-31 | $853.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | $1.45M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $981.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | $1.00M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $1.18M 10-Q · filed 2021-11-04 |
| 2020-09-30 | $925.00K 10-Q · filed 2020-11-06 |
| 2020-06-30 | $1.10M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $1.30M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $1.38M 10-K · filed 2021-03-01 |
| 2018-12-31 | $47.00K 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |